Inclusion Criteria:  Radiographic disease progression during or following at least 6 weeks of treatment with ICI for locally advanced or metastatic RCC with a clear cell component either in first- or second-line treatment. Subjects must have recovered from the adverse events of prior therapy or returned to baseline. Histologically or cytologically confirmed RCC with a clear cell component. Measurable disease per RECIST criteria Version 1.1. Eastern Cooperative Oncology Group performance status of 0 or 1.  Exclusion Criteria:  More than 2 prior lines of therapy in the advanced or metastatic setting. History of life-threatening toxicity related to prior immune therapy. Active, known, or suspected autoimmune disease. Uncontrolled hypertension. More than 1 prior line of therapy with a checkpoint inhibitor in the metastatic setting.